EIC-Transition partnership to treat resistant bacterial infections by new FPR1 agonists

Important results from the project

We have reached all objectives in the project regarding technical validation, market analyzes, and patent analysis. EIC Transition-application was submitted 18th september (iCURE #10121281). We have carried out validations in human cells and animal models, regulatory analysis, toxicological planning, medicinal chemistry and market analyses, and submitted a patent application in the UK. The project has led to strengthened international collaborations and a clearer R&D and business plan.

Expected long term effects

We have established a focused R&D plan, which led to the formation of the spinoff company Inicure AB. With support from GU Venture, we are evaluated for support from Scilife and Incate (www.incate.net). We have strengthened our IP with a patent application and developed a plan for partnership with biotech/pharma. We believe our innovative drug candidate can enable a new treatment that could save hundreds of thousands of lives, reduce hospital costs and have global commercial potential.

Approach and implementation

The work on the proposal was carried out according to plan; - Monthly meetings with the entire consortium, and continuous work with proposal - Meeting with partners in UK, University of Swansea in Wales. - Technical validation of partners in the UK (London and Wales) - Analyzes for chemistry, toxicology and regulatory drug plan. - IP analyzes with pharmaceutical chemists and patent advisors, as well as submitted patent applications - Advice and review of proposal in two stages from EUSME.